LINDSAY BITTO: Open Payments
NPI 1972904845 · FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,985 in 91 payments from 26 companies in 2025. Trend: 2023 $2,049 · 2024 $2,038 · 2025 $2,985
Food & beverage: $2,975Education: $9
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $430 |
| Madrigal Pharmaceuticals | 8 | $357 |
| GENZYME CORPORATION | 13 | $276 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $240 |
| Janssen Biotech, Inc. | 9 | $233 |
| Amgen Inc. | 2 | $205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $135 |
| Dexcom, Inc. | 1 | $115 |
| Teva Pharmaceuticals USA, Inc. | 1 | $103 |
| Lilly USA, LLC | 4 | $94 |
Products named: DUPIXENT, REZDIFFRA, RINVOQ, XIFAXAN, TREMFYA, DEXCOM G7 GSS (161), ENTYVIO, REPATHA.
Industry payments across MD — which companies pay providers there.
